In order to examine whether the nuclear translocation of NF-κB has an effect on CCND1 expression, we used the NF-κB inhibitor SN50, which can effectively inhibit the nuclear translocation of NF-κB, to treat lung cancer cells. Here, NFKB1 is linked to lung cancer.